$AHR
American Healthcare REIT, Inc. Stock $ahr

$ahr Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000163297017000063 Filed on May 10, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$4.052M	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.711M	$0.00
YoY Change
% of Gross Profit
Operating Expenses
YoY Change
Operating Profit	$333.0K	-$150.0K
YoY Change	-322.0%
Interest Expense	$418.0K	$0.00
YoY Change
% of Operating Profit	125.53%
Other Income/Expense, Net	$418.0K	$0.00
YoY Change
Pretax Income
YoY Change
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$85.00K	-$150.0K
YoY Change	-43.33%
Net Earnings / Revenue	-2.1%
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding		20.83K shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$2.059M	$202.0K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$23.16M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets	$218.0M	$428.0K
YoY Change	50830.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities
Total Liabilities	$58.90M	$344.0K
YoY Change	17021.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$9.607M	-$150.0K
YoY Change	6304.67%
Common Stock		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$82.00K
YoY Change
Total Liabilities & Shareholders Equity	$218.0M	$428.0K
YoY Change	50830.84%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$85.00K	-$150.0K
YoY Change	-43.33%
Depreciation, Depletion And Amortization	$1.711M	$0.00
YoY Change
Cash From Operating Activities	$1.390M	$0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$75.55M	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$76.13M	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$73.99M	$0.00
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	$1.390M	$0.00
Cash From Investing Activities	-$75.55M	$0.00
Cash From Financing Activities	$73.99M	$0.00
Net Change In Cash	-$178.0K	$0.00
YoY Change		-100.0%
FREE CASH FLOW
Cash From Operating Activities	$1.390M	$0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001632970
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2015-01-23
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	Griffin-American Healthcare REIT IV, Inc.
CY2017Q1	dei	Trading Symbol TradingSymbol	gahr4
CY2016Q1	gahr	Accrued Contingent Advisor Payment AccruedContingentAdvisorPayment	0	USD
CY2017Q1	gahr	Accrued Contingent Advisor Payment AccruedContingentAdvisorPayment	7456000	USD
CY2016Q1	gahr	Accruedstockholderservicingfee Accruedstockholderservicingfee	0	USD
CY2017Q1	gahr	Accruedstockholderservicingfee Accruedstockholderservicingfee	6540000	USD
	gahr	Acquisition Aggregated Cost Of Acquired Properties Purchase Price AcquisitionAggregatedCostOfAcquiredPropertiesPurchasePrice	212370000	USD
CY2017	gahr	Advisory Agreement Term AdvisoryAgreementTerm	P1Y
CY2016Q1	gahr	Aggregate Maximum Amount Of Common Stock Issuable Under Public Offering AggregateMaximumAmountOfCommonStockIssuableUnderPublicOffering	3150000000	USD
CY2016Q2	gahr	Aggregate Reallocated Maximum Amountof Common Stock Issuable Under Primary Public Offering AggregateReallocatedMaximumAmountofCommonStockIssuableUnderPrimaryPublicOffering	3150000000	USD
CY2016Q1	gahr	Amortizationof Identified Intangible Liabilities AmortizationofIdentifiedIntangibleLiabilities	0	USD
CY2017Q1	gahr	Amortizationof Identified Intangible Liabilities AmortizationofIdentifiedIntangibleLiabilities	68000	USD
CY2017Q1	gahr	Amortizationofdeferredfinancingcostsrelatedtomortgage Amortizationofdeferredfinancingcostsrelatedtomortgage	2000	USD
CY2017Q1	gahr	Capitalized Acquisition Costsand Fees Additions CapitalizedAcquisitionCostsandFeesAdditions	1818000	USD
CY2017Q1	gahr	Capitalizeddeferredfinancingcostsformortgages Capitalizeddeferredfinancingcostsformortgages	4000	USD
CY2016Q1	gahr	Dealer Manager Fees DealerManagerFees	0	USD
CY2017Q1	gahr	Dealer Manager Fees DealerManagerFees	733000	USD
CY2017Q1	gahr	Finite Lived Intangible Liabilities Amortization Expenses After Year Five FiniteLivedIntangibleLiabilitiesAmortizationExpensesAfterYearFive	583000	USD
CY2017Q1	gahr	Finite Lived Intangible Liabilities Amortization Expenses Remainder Of Fiscal Year FiniteLivedIntangibleLiabilitiesAmortizationExpensesRemainderOfFiscalYear	210000	USD
CY2017Q1	gahr	Finite Lived Intangible Liabilities Amortization Expenses Year Five FiniteLivedIntangibleLiabilitiesAmortizationExpensesYearFive	65000	USD
CY2017Q1	gahr	Finite Lived Intangible Liabilities Amortization Expenses Year Four FiniteLivedIntangibleLiabilitiesAmortizationExpensesYearFour	88000	USD
CY2017Q1	gahr	Finite Lived Intangible Liabilities Amortization Expenses Year Three FiniteLivedIntangibleLiabilitiesAmortizationExpensesYearThree	251000	USD
CY2017Q1	gahr	Finite Lived Intangible Liabilities Amortization Expenses Year Two FiniteLivedIntangibleLiabilitiesAmortizationExpensesYearTwo	279000	USD
CY2016Q4	gahr	Finite Lived Intangible Liabilities Net FiniteLivedIntangibleLiabilitiesNet	1063000	USD
CY2017Q1	gahr	Finite Lived Intangible Liabilities Net FiniteLivedIntangibleLiabilitiesNet	1476000	USD
CY2017Q1	gahr	Finite Lived Intangible Liabilities Net FiniteLivedIntangibleLiabilitiesNet	1476000	USD
CY2016	gahr	Finite Lived Intangible Liabilities Useful Life FiniteLivedIntangibleLiabilitiesUsefulLife	P5Y4M24D
CY2017Q1	gahr	Finite Lived Intangible Liabilities Useful Life FiniteLivedIntangibleLiabilitiesUsefulLife	P18Y4M24D
CY2016Q3	gahr	Line Of Credit Facility Number Of Potential Extensions LineOfCreditFacilityNumberOfPotentialExtensions	1	Extension
CY2016Q3	gahr	Line Of Credit Facility Potential Extension Term LineOfCreditFacilityPotentialExtensionTerm	P12M
CY2016Q3	gahr	Line Of Credit Facility Potential Increase Amount To Borrowing Capacity LineOfCreditFacilityPotentialIncreaseAmountToBorrowingCapacity	100000000	USD
CY2016Q3	gahr	Line Of Credit Facility Potential Maximum Borrowing Capacity LineOfCreditFacilityPotentialMaximumBorrowingCapacity	200000000	USD
CY2016Q4	gahr	Lineofcreditcarryingvalue Lineofcreditcarryingvalue	32957000	USD
CY2017Q1	gahr	Lineofcreditcarryingvalue Lineofcreditcarryingvalue	34744000	USD
CY2016Q1	gahr	Maximum Investment Rate By Officer Evp MaximumInvestmentRateByOfficerEVP	0.150
CY2016Q4	gahr	Maximum Investment Rate By Officer Evp MaximumInvestmentRateByOfficerEVP	0.150
	gahr	Maximum Percentage Of Common Stock Repurchased During Period MaximumPercentageOfCommonStockRepurchasedDuringPeriod	0.050
CY2017Q1	gahr	Maximum Percentage Of Fees And Expenses Associated With Acquisition MaximumPercentageOfFeesAndExpensesAssociatedWithAcquisition	0.060
	gahr	Maximumpercentageofdealermanagerfee Maximumpercentageofdealermanagerfee	0.030
CY2017Q1	gahr	Maximumpercentageofdealermanagerfee Maximumpercentageofdealermanagerfee	0.030
CY2017Q1	gahr	Maximumpercentageofstockholderservicingfee Maximumpercentageofstockholderservicingfee	0.040
CY2016Q1	gahr	Minimum Investment Rate By Officer Evp MinimumInvestmentRateByOfficerEVP	0.100
CY2016Q4	gahr	Minimum Investment Rate By Officer Evp MinimumInvestmentRateByOfficerEVP	0.050
CY2017Q1	gahr	Minimum Percent Share Of Annualized Base Rent Accounted By Tenants MinimumPercentShareOfAnnualizedBaseRentAccountedByTenants	0.100
CY2017Q1	gahr	Minimum Percent Share Of Each State Annualized Base Rent That Company Owned MinimumPercentShareOfEachStateAnnualizedBaseRentThatCompanyOwned	0.1
CY2016Q1	gahr	Noncashreclassificationofnoncontrollinginterest Noncashreclassificationofnoncontrollinginterest	2000	USD
CY2017Q1	gahr	Noncashreclassificationofnoncontrollinginterest Noncashreclassificationofnoncontrollinginterest	0	USD
	gahr	Number Of Buildings Acquired From Unaffiliated Parties NumberOfBuildingsAcquiredFromUnaffiliatedParties	14	Building
CY2016Q4	gahr	Number Of Fixed Rate Mortgage Loans Payable NumberOfFixedRateMortgageLoansPayable	1	MortgageLoan
CY2017Q1	gahr	Number Of Fixed Rate Mortgage Loans Payable NumberOfFixedRateMortgageLoansPayable	1	MortgageLoan
CY2017Q1	gahr	Number Of Tenants With More Than Ten Percent Of Annual Base Rent NumberOfTenantsWithMoreThanTenPercentOfAnnualBaseRent	1
	gahr	Numberof Acquisitions Completedfrom Unaffiliated Parties NumberofAcquisitionsCompletedfromUnaffiliatedParties	11	Acquisition
CY2017Q1	gahr	Numberof Acquisitions Completedfrom Unaffiliated Parties NumberofAcquisitionsCompletedfromUnaffiliatedParties	2	Acquisition
CY2016Q1	gahr	Officer Purchase Share Price OfficerPurchaseSharePrice	9.60
CY2016Q1	gahr	Other Amortization OtherAmortization	0	USD
CY2017Q1	gahr	Other Amortization OtherAmortization	77000	USD
CY2017Q1	gahr	Ownership Percentage Properties OwnershipPercentageProperties	1.00
	gahr	Percentage Of Dealer Manager Fee PercentageOfDealerManagerFee	0.010
	gahr	Percentage Of Dealer Manager Fee PercentageOfDealerManagerFee	0.010
	gahr	Percentage Of Dealer Manager Fee PercentageOfDealerManagerFee	0.010
CY2016Q4	gahr	Prepaid Expenses And Deposits PrepaidExpensesAndDeposits	257000	USD
CY2017Q1	gahr	Prepaid Expenses And Deposits PrepaidExpensesAndDeposits	782000	USD
CY2017Q1	gahr	Receivable From Transfer Agent ReceivableFromTransferAgent	521000	USD
CY2016Q1	gahr	Receivable From Transfer Agent ReceivableFromTransferAgent	0	USD
CY2017Q1	gahr	Reclassificationof Noncontrolling Interest ReclassificationofNoncontrollingInterest	0	USD
CY2016Q1	gahr	Selling Commissions Expenses SellingCommissionsExpenses	0	USD
CY2016Q1	gahr	Reclassificationof Noncontrolling Interest ReclassificationofNoncontrollingInterest	2000	USD
CY2016Q1	gahr	Reclassificationof Noncontrolling Interest ReclassificationofNoncontrollingInterest	2000	USD
CY2017Q1	gahr	Selling Commissions Expenses SellingCommissionsExpenses	2070000	USD
	gahr	Selling Commissions Percentage SellingCommissionsPercentage	0.030
CY2017Q1	gahr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Expected To Vest Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber	12000	shares
CY2017Q1	gahr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Expected To Vest Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue	10.00
	gahr	Share Repurchase Plan Holding Period Condition One ShareRepurchasePlanHoldingPeriodConditionOne	P1Y
CY2017Q1	gahr	Share Repurchase Plan Percentageof Priceper Share Condition One ShareRepurchasePlanPercentageofPriceperShareConditionOne	0.925
CY2017Q1	gahr	Share Repurchase Plan Percentageof Priceper Share Condition Two ShareRepurchasePlanPercentageofPriceperShareConditionTwo	1.00
CY2016Q1	gahr	Sharesissuedindiscount Sharesissuedindiscount	0	USD
CY2017Q1	gahr	Sharesissuedindiscount Sharesissuedindiscount	3000	USD
CY2016Q1	gahr	Stockholder Servicing Fee Incurred StockholderServicingFeeIncurred	0	USD
CY2017Q1	gahr	Stockholder Servicing Fee Incurred StockholderServicingFeeIncurred	2754000	USD
CY2016Q4	gahr	Stockholder Servicing Fee Payable StockholderServicingFeePayable	3973000	USD
CY2017Q1	gahr	Stockholder Servicing Fee Payable StockholderServicingFeePayable	6540000	USD
	gahr	Stockholderdailyservicingfeepercentage Stockholderdailyservicingfeepercentage	0.010
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	5426000	USD
CY2017Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	9490000	USD
CY2016Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1299000	USD
CY2017Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	741000	USD
CY2016Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	112000	USD
CY2017Q1	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	199000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	99492000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	168499000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	32000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	87000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	628000	USD
CY2017Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	860000	sqft
CY2016Q1	us-gaap	Asset Management Fees1 AssetManagementFees1	0	USD
CY2017Q1	us-gaap	Asset Management Fees1 AssetManagementFees1	301000	USD
CY2016Q4	us-gaap	Assets Assets	142758000	USD
CY2016Q4	us-gaap	Assets Assets	142758000	USD
CY2017Q1	us-gaap	Assets Assets	217984000	USD
CY2017Q1	us-gaap	Assets Assets	217984000	USD
CY2016Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	USD
CY2017Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	73000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	669000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	202000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	202000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2237000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2237000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2059000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2059000	USD
CY2016Q1	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	0	USD
CY2017Q1	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-178000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.00
CY2017Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.15
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2016Q1	us-gaap	Cost Of Real Estate Revenue CostOfRealEstateRevenue	0	USD
CY2017Q1	us-gaap	Cost Of Real Estate Revenue CostOfRealEstateRevenue	1187000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	150000	USD
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	3719000	USD
CY2016Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0	USD
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3908000	USD
CY2017Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3845000	USD
CY2016Q4	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.0430
CY2017Q1	us-gaap	Debt Weighted Average Interest Rate DebtWeightedAverageInterestRate	0.0455
CY2016Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	943000	USD
CY2017Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	856000	USD
CY2016Q4	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	207000	USD
CY2017Q1	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	480000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	1140000	USD
CY2016Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0	USD
CY2017Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1711000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	0	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1711000	USD
CY2016Q1	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	USD
CY2017Q1	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	885000	USD
CY2016Q4	us-gaap	Due To Affiliate Current And Noncurrent DueToAffiliateCurrentAndNoncurrent	5531000	USD
CY2017Q1	us-gaap	Due To Affiliate Current And Noncurrent DueToAffiliateCurrentAndNoncurrent	7620000	USD
CY2016Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	5531000	USD
CY2017Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	7620000	USD
CY2016Q4	us-gaap	Earnest Money Deposits EarnestMoneyDeposits	200000	USD
CY2017Q1	us-gaap	Earnest Money Deposits EarnestMoneyDeposits	1000000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.20
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2016	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P28Y7M6D
CY2017Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P25Y
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	10953000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2314000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1913000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2264000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2778000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2938000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23160000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	150000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	150000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	748000	USD
CY2016Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2017Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	0	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-50000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	37000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	429000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	307000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	37000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-165000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	226000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	422000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	19673000	USD
CY2017Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23160000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	418000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	0	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	356000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	50501000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	58899000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	142758000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	217984000	USD
CY2016	us-gaap	Limited Liability Company Llc Or Limited Partnership Lp Managing Member Or General Partner Ownership Interest LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest	0.9999
CY2017Q1	us-gaap	Limited Liability Company Llc Or Limited Partnership Lp Managing Member Or General Partner Ownership Interest LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest	0.9999
CY2016	us-gaap	Limited Liability Company Llc Or Limited Partnership Lp Members Or Limited Partners Ownership Interest LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest	0.0001
CY2017Q1	us-gaap	Limited Liability Company Llc Or Limited Partnership Lp Members Or Limited Partners Ownership Interest LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest	0.0001
CY2016Q4	us-gaap	Line Of Credit LineOfCredit	33900000	USD
CY2016Q4	us-gaap	Line Of Credit LineOfCredit	33900000	USD
CY2017Q1	us-gaap	Line Of Credit LineOfCredit	35600000	USD
CY2017Q1	us-gaap	Line Of Credit LineOfCredit	35600000	USD
CY2016Q3	us-gaap	Line Of Credit Facility Collateral LineOfCreditFacilityCollateral	750000000
CY2016Q4	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	33899000	USD
CY2017Q1	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	35600000	USD
CY2017Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	100000000	USD
CY2016Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	66100000	USD
CY2017Q1	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	64400000	USD
CY2016Q4	us-gaap	Loans Payable Fair Value Disclosure LoansPayableFairValueDisclosure	4131000	USD
CY2017Q1	us-gaap	Loans Payable Fair Value Disclosure LoansPayableFairValueDisclosure	4045000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	2492000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	314000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	192000	USD
CY2016Q4	us-gaap	Minority Interest Ownership Percentage By Noncontrolling Owners MinorityInterestOwnershipPercentageByNoncontrollingOwners	0.0001
CY2017Q1	us-gaap	Minority Interest Ownership Percentage By Noncontrolling Owners MinorityInterestOwnershipPercentageByNoncontrollingOwners	0.0001
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	297000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	282000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	268000	USD
CY2016Q4	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.9999
CY2017Q1	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.9999
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	73985000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-75553000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1390000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-150000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-85000	USD
CY2016Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	USD
CY2016Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	USD
CY2017Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	USD
CY2017Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	USD
CY2016Q1	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	0	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	103000	USD
CY2016Q1	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	0	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	360000	USD
CY2016Q1	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	125000	USD
CY2017Q1	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	3	State
CY2016Q4	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	1063000	USD
CY2017Q1	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	1476000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-150000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	333000	USD
CY2016Q1	us-gaap	Operating Leases Income Statement Lease Revenue OperatingLeasesIncomeStatementLeaseRevenue	0	USD
CY2016Q1	us-gaap	Operating Leases Income Statement Lease Revenue OperatingLeasesIncomeStatementLeaseRevenue	0	USD
CY2017Q1	us-gaap	Operating Leases Income Statement Lease Revenue OperatingLeasesIncomeStatementLeaseRevenue	4052000	USD
CY2017Q1	us-gaap	Operating Leases Income Statement Lease Revenue OperatingLeasesIncomeStatementLeaseRevenue	4052000	USD
	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2015-02-06
CY2016Q4	us-gaap	Other Assets OtherAssets	1407000	USD
CY2016Q4	us-gaap	Other Assets OtherAssets	1407000	USD
CY2017Q1	us-gaap	Other Assets OtherAssets	2118000	USD
CY2017Q1	us-gaap	Other Assets OtherAssets	2118000	USD
CY2016Q4	us-gaap	Other Liabilities OtherLiabilities	616000	USD
CY2017Q1	us-gaap	Other Liabilities OtherLiabilities	812000	USD
CY2016Q1	us-gaap	Owned Property Management Costs OwnedPropertyManagementCosts	0	USD
CY2017Q1	us-gaap	Owned Property Management Costs OwnedPropertyManagementCosts	1187000	USD
CY2016Q1	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	0	USD
CY2017Q1	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	2000	USD
CY2016Q1	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	0	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3009000	USD
CY2017Q1	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	39000	USD
CY2016Q1	us-gaap	Payments For Proceeds From Deposits On Real Estate Acquisitions PaymentsForProceedsFromDepositsOnRealEstateAcquisitions	0	USD
CY2017Q1	us-gaap	Payments For Proceeds From Deposits On Real Estate Acquisitions PaymentsForProceedsFromDepositsOnRealEstateAcquisitions	800000	USD
CY2016Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	0	USD
CY2017Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	755000	USD
CY2016Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2017Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	14000	USD
CY2016Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2016Q1	us-gaap	Payments To Acquire Real Estate PaymentsToAcquireRealEstate	0	USD
CY2017Q1	us-gaap	Payments To Acquire Real Estate PaymentsToAcquireRealEstate	74714000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	76125000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock Dividend Reinvestment Plan ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan	796000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock Dividend Reinvestment Plan ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan	1859000	USD
CY2016Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2017Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	60000000	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	-150000	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	-150000	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	-85000	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	-85000	USD
CY2016Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2017Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14000	USD
CY2016Q4	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	822000	USD
CY2017Q1	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	1962000	USD
CY2016Q4	us-gaap	Real Estate Investment Property At Cost RealEstateInvestmentPropertyAtCost	118764000	USD
CY2017Q1	us-gaap	Real Estate Investment Property At Cost RealEstateInvestmentPropertyAtCost	190868000	USD
CY2016Q4	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	117942000	USD
CY2016Q4	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	117942000	USD
CY2017Q1	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	188906000	USD
CY2017Q1	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	188906000	USD
CY2015Q4	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	0	USD
CY2016Q1	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	2000	USD
CY2016Q4	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	2000	USD
CY2016Q4	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	2000	USD
CY2017Q1	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	2000	USD
CY2017Q1	us-gaap	Redeemable Noncontrolling Interest Equity Fair Value RedeemableNoncontrollingInterestEquityFairValue	2000	USD
CY2016Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	307000	USD
CY2017Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	4089000	USD
CY2016Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2017Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	58300000	USD
CY2017Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	62000	USD
CY2016Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	USD
CY2017Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	62000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7351000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9607000	USD
CY2016Q1	us-gaap	Revenues Revenues	0	USD
CY2017Q1	us-gaap	Revenues Revenues	2865000	USD
CY2016Q4	us-gaap	Secured Debt SecuredDebt	3965000	USD
CY2017Q1	us-gaap	Secured Debt SecuredDebt	3901000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	32000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	14000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.00
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	12000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	12000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	10
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	10.00
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	0	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.00
CY2016Q4	us-gaap	Shares Issued SharesIssued	11377439	shares
CY2017Q1	us-gaap	Shares Issued SharesIssued	19099914	shares
CY2016Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2017Q1	us-gaap	Stock Issued1 StockIssued1	1063000	USD
	us-gaap	Stock Issued During Period Shares Dividend Reinvestment Plan StockIssuedDuringPeriodSharesDividendReinvestmentPlan	196864	shares
CY2016	us-gaap	Stock Issued During Period Shares Dividend Reinvestment Plan StockIssuedDuringPeriodSharesDividendReinvestmentPlan	83717	shares
CY2017Q1	us-gaap	Stock Issued During Period Shares Dividend Reinvestment Plan StockIssuedDuringPeriodSharesDividendReinvestmentPlan	196864	shares
CY2017Q1	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	1063000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	202000	USD
CY2016Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	82000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	92255000	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	159083000	USD
CY2016Q1	us-gaap	Straight Line Rent Adjustments StraightLineRentAdjustments	0	USD
CY2017Q1	us-gaap	Straight Line Rent Adjustments StraightLineRentAdjustments	-273000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20833	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14655107	shares
CY2017Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. Organization and Description of Business</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Griffin-American Healthcare REIT IV, Inc., a Maryland corporation, was incorporated on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 23, 2015</font><font style="font-family:inherit;font-size:10pt;"> and therefore we consider that our date of inception. We were initially capitalized on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">February 6, 2015</font><font style="font-family:inherit;font-size:10pt;">. We invest in a diversified portfolio of real estate properties, focusing primarily on medical office buildings, hospitals, skilled nursing facilities, senior housing and other healthcare-related facilities. We may also originate and acquire secured loans and real estate-related investments on an infrequent and opportunistic basis. We generally seek investments that produce current income. We believe we currently qualify, and intend to elect to be treated, as a real estate investment trust, or REIT, under the Internal Revenue Code of 1986, as amended, or the Code, for federal income tax purposes beginning with our taxable year ended December 31, 2016, and we intend to continue to be taxed as a REIT.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 16, 2016, we commenced our initial public offering, or our offering, in which we were offering to the public up to </font><font style="font-family:inherit;font-size:10pt;">$3,150,000,000</font><font style="font-family:inherit;font-size:10pt;"> in shares of our Class T common stock, consisting of up to </font><font style="font-family:inherit;font-size:10pt;">$3,000,000,000</font><font style="font-family:inherit;font-size:10pt;"> in shares of our Class T common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$10.00</font><font style="font-family:inherit;font-size:10pt;"> per share in our primary offering and up to </font><font style="font-family:inherit;font-size:10pt;">$150,000,000</font><font style="font-family:inherit;font-size:10pt;"> in shares of our Class T common stock for </font><font style="font-family:inherit;font-size:10pt;">$9.50</font><font style="font-family:inherit;font-size:10pt;"> per share pursuant to our distribution reinvestment plan, as amended, or the DRIP. Effective June 17, 2016, we reallocated certain of the unsold shares of Class T common stock being offered and began offering shares of Class I common stock, such that we are currently offering up to approximately </font><font style="font-family:inherit;font-size:10pt;">$2,800,000,000</font><font style="font-family:inherit;font-size:10pt;"> in shares of Class T common stock and </font><font style="font-family:inherit;font-size:10pt;">$200,000,000</font><font style="font-family:inherit;font-size:10pt;"> in shares of Class I common stock in our primary offering, and up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$150,000,000</font><font style="font-family:inherit;font-size:10pt;"> in shares of our Class T and Class I common stock pursuant to the DRIP, aggregating up to </font><font style="font-family:inherit;font-size:10pt;">$3,150,000,000</font><font style="font-family:inherit;font-size:10pt;">. The shares of our Class T common stock in our primary offering are being offered at a price of </font><font style="font-family:inherit;font-size:10pt;">$10.00</font><font style="font-family:inherit;font-size:10pt;"> per share. The shares of our Class I common stock in our primary offering were being offered at a price of </font><font style="font-family:inherit;font-size:10pt;">$9.30</font><font style="font-family:inherit;font-size:10pt;"> per share prior to March 1, 2017, and are being offered at a price of </font><font style="font-family:inherit;font-size:10pt;">$9.21</font><font style="font-family:inherit;font-size:10pt;"> per share for all shares offered effective March 1, 2017. The shares of our Class T and Class I common stock issued pursuant to the DRIP were sold at a price of </font><font style="font-family:inherit;font-size:10pt;">$9.50</font><font style="font-family:inherit;font-size:10pt;"> per share prior to January 1, 2017, and are sold at a price of </font><font style="font-family:inherit;font-size:10pt;">$9.40</font><font style="font-family:inherit;font-size:10pt;"> per share for all shares issued pursuant to the DRIP effective January 1, 2017. After our board of directors determines an estimated net asset value, or NAV, per share of our common stock, share prices are expected to be adjusted to reflect the estimated NAV per share and, in the case of shares offered pursuant to our primary offering, up-front selling commissions and dealer manager fees other than those funded by Griffin-American Healthcare REIT IV Advisor, LLC, or Griffin-American Healthcare REIT IV Advisor, or our advisor. We reserve the right to reallocate the shares of common stock we are offering between the primary offering and the DRIP, and among classes of stock. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had received and accepted subscriptions in our offering for </font><font style="font-family:inherit;font-size:10pt;">18,867,217</font><font style="font-family:inherit;font-size:10pt;"> aggregate shares of our Class T and Class I common stock, or approximately </font><font style="font-family:inherit;font-size:10pt;">$187,691,000</font><font style="font-family:inherit;font-size:10pt;">, excluding shares of our common stock issued pursuant to the DRIP. </font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conduct substantially all of our operations through Griffin-American Healthcare REIT IV Holdings, LP, or our operating partnership. We are externally advised by our advisor pursuant to an advisory agreement, or the Advisory Agreement, between us and our advisor. The Advisory Agreement was effective as of February 16, 2016 and had a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year term, subject to successive </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year renewals upon the mutual consent of the parties. The Advisory Agreement was renewed pursuant to the mutual consent of the parties on February 13, 2017 and expires on February 16, 2018. Our advisor uses its best efforts, subject to the oversight and review of our board of directors, to, among other things, research, identify, review and make investments in and dispositions of properties and securities on our behalf consistent with our investment policies and objectives. Our advisor performs its duties and responsibilities under the Advisory Agreement as our fiduciary. Our advisor is </font><font style="font-family:inherit;font-size:10pt;">75.0%</font><font style="font-family:inherit;font-size:10pt;"> owned and managed by American Healthcare Investors, LLC, or American Healthcare Investors, and </font><font style="font-family:inherit;font-size:10pt;">25.0%</font><font style="font-family:inherit;font-size:10pt;"> owned by a wholly owned subsidiary of Griffin Capital Company, LLC, or Griffin Capital (formerly known as Griffin Capital Corporation), or collectively, our co-sponsors. Effective March 1, 2015, American Healthcare Investors is </font><font style="font-family:inherit;font-size:10pt;">47.1%</font><font style="font-family:inherit;font-size:10pt;"> owned by AHI Group Holdings, LLC, or AHI Group Holdings, </font><font style="font-family:inherit;font-size:10pt;">45.1%</font><font style="font-family:inherit;font-size:10pt;"> indirectly owned by Colony NorthStar, Inc. (NYSE: CLNS), or Colony NorthStar (formerly known as NorthStar Asset Management Group Inc. prior to its merger with Colony Capital, Inc. and NorthStar Realty Finance Corp. on January 10, 2017), and </font><font style="font-family:inherit;font-size:10pt;">7.8%</font><font style="font-family:inherit;font-size:10pt;"> owned by James F. Flaherty III, one of Colony NorthStar’s partners. We are not affiliated with Griffin Capital, Griffin Capital Securities, LLC, or our dealer manager, Colony NorthStar or Mr. Flaherty; however, we are affiliated with Griffin-American Healthcare REIT IV Advisor, American Healthcare Investors and AHI Group Holdings.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently operate through two reportable business segments — medical office buildings and senior housing. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had completed </font><font style="font-family:inherit;font-size:10pt;">11</font><font style="font-family:inherit;font-size:10pt;"> property acquisitions comprising </font><font style="font-family:inherit;font-size:10pt;">14</font><font style="font-family:inherit;font-size:10pt;"> buildings, or approximately </font><font style="font-family:inherit;font-size:10pt;">860,000</font><font style="font-family:inherit;font-size:10pt;"> square feet of gross leasable area, or GLA, for an aggregate contract purchase price of </font><font style="font-family:inherit;font-size:10pt;">$212,370,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:10px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of our accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the disclosure of contingent assets and liabilities, at the date of our condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are made and evaluated on an on-going basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates, perhaps in material adverse ways, and those estimates could be different under different assumptions or conditions.</font></div></div>

Files In Submission

Name	View Source	Status
0001632970-17-000063-index-headers.html	Edgar Link	pending
0001632970-17-000063-index.html	Edgar Link	pending
0001632970-17-000063.txt	Edgar Link	pending
0001632970-17-000063-xbrl.zip	Edgar Link	pending
ex311-gahr4x10xq2017xq1.htm	Edgar Link	pending
ex312-gahr4x10xq2017xq1.htm	Edgar Link	pending
ex321-gahr4x10xq2017xq1.htm	Edgar Link	pending
ex322-gahr4x10xq2017xq1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gahr-20170331.xml	Edgar Link	completed
gahr-20170331.xsd	Edgar Link	pending
gahr-20170331_cal.xml	Edgar Link	unprocessable
gahr-20170331_def.xml	Edgar Link	unprocessable
gahr-20170331_lab.xml	Edgar Link	unprocessable
gahr-20170331_pre.xml	Edgar Link	unprocessable
gahr4-10xq2017xq1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AHR
American Healthcare REIT, Inc. Stock $ahr

2017 Q1 Form 10-Q Financial Statement

#000163297017000063 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AHR American Healthcare REIT, Inc. Stock $ahr

2017 Q1 Form 10-Q Financial Statement

#000163297017000063 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AHR
American Healthcare REIT, Inc. Stock $ahr